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Abstract
Background: Attention deficit hyperactivity disorder (ADHD) in adulthood is not fully treated by
psychopharmacological treatment alone. The main aim of the current study was to evaluate a newly developed
cognitive behaviour therapy (CBT) based group programme, the Reasoning and Rehabilitation for ADHD Youths
and Adults (R&R2ADHD), using a randomized controlled trial.
Methods: 54 adults with ADHD already receiving psychopharmacological treatment were randomly allocated to an
experimental (CBT/MED) treatment condition (n = 27) and a ‘treatment as usual’ (TAU/MED) control condition (n =
27) that did not receive the CBT intervention. The outcome measures were obtained before treatment (baseline),
after treatment and at three month follow-up and included ADHD symptoms and impairments rated by
independent assessors, self-reported current ADHD symptoms, and comorbid problems.
Results: The findings suggested medium to large treatment effects for ADHD symptoms, which increased further
at three month follow-up. Additionally, comorbid problems also improved at follow-up with large effect sizes.
Conclusions: The findings give support for the effectiveness of R&R2ADHD in reducing ADHD symptoms and
comorbid problems, an improving functions associated with impairment. The implications are that the benefits of
R&R2ADHD are multifaceted and that combined psychopharmacological and CBT based treatments may add to
and improve pharmacological interventions.
Trial registration: ACTRN12611000533998 (http://www.ANZCTR.org.au/ACTRN12611000533998.aspx)
Background
In the last decade ADHD among adults has become
increasingly recognized as a complex disorder character-
ized by high rates of comorbidity and social dysfunction,
including mood disorders, anxiety, alcohol and drug
abuse, educational failure, occupational problems, inter-
personal relationship problems, delinquency and crime
[1-4]. Population surveys estimate the prevalence of
ADHD in adults to be around 2.5% [5].
Many adults do not obtain their diagnosis until their
adult years yet even when ADHD has been recognized
and treated in childhood psychiatric and psychosocial
outcomes are bleak [6,7]. The costs associated with the
disorder are serious and long-term [8].
In addition to high rates of comorbidity, adult ADHD
has been associated with maladaptive personality (i.e. a
disorganized personality style) and maladaptive coping
strategies which limits the internal resources available to
the individual [9,10]. Thus treatments need to not only
target symptom reduction, but aim to improve quality
of life by addressing the multiple problems that impair
daily social and emotional functioning [11].
International guidelines [8,12] recommend multimodal
treatment for adults with ADHD comprising of psychoe-
ducation, pharmacotherapy and cognitive behaviour
therapy (CBT). The need for non-pharmacological inter-
ventions is underpinned by the finding that some adults
do not respond to drug treatment and those who do
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may only experience a partial response [13]. In the past
few years prescribing has increased for treating ADHD
[14], yet psychological treatments have not paralleled
this growth [2,15].
Research on the effectiveness of psychopharmacological
treatments in ADHD adults has been extensive compared
with evaluations of psychological interventions. Only six
randomised controlled studies have been published and
these all report effectiveness of CBT interventions in
medicated patients. CBT provided on an individual basis
has been evaluated by Safren and colleagues [16] who ran-
domly assigned 31 patients receiving medication to receive
15 sessions of CBT or treatment as usual. They found that
combined medication and CBT had a greater effect for
independent evaluator ratings of ADHD symptoms,
impairment and depression and for self-reported ADHD
symptoms and anxiety. They later conducted another
study randomizing medicated patients to either 12 ses-
sions of CBT or relaxation with educational support and
found similar results for ADHD symptom reduction [17].
Importantly, improvements for those who responded to
treatment were maintained at 12 month follow up. In a
study of 29 adults with ADHD (medication not controlled
for) comparing 10 sessions of individual CBT with 20 ses-
sions of cognitive training (CT; training of attention,
executive functions and working memory) and a control
condition, a significant effect was only found for self-
reported inattention. No effect was found on independent
evaluations, or on independent and self-ratings for mea-
sures of ADHD symptoms, depression or quality of life
[18].
Group interventions are attractive for clinical delivery as
they are cost effective, thus group interventions were
recommended by the National Institute for Health and
Clinical Excellence [NICE] as the first line psychological
treatment. Solanto and colleagues [19] evaluated a 12 ses-
sion group CBT programme by randomly assigning 88
patients receiving medication to receive either CBT or sup-
portive therapy. The CBT condition had lower treatment
dropout and found significant effect for self-report, collat-
eral report and independent evaluator ratings of inattention
symptoms. No significant effect was found for comorbid
problems (depression, anxiety and self-esteem) or for orga-
nization and planning skills. A similar pattern of outcome
was reported by Hirvikoski and colleagues [20] who ran-
domly assigned 51 medicated adults to 14 sessions of dia-
lectical behaviour therapy (DBT) or a loosely structured
discussion group. A significantly greater reduction in
ADHD symptoms was self-reported at the end of DBT
group treatment but no significant difference was found
for comorbid depression, anxiety, sleep problems, stress or
functional impairment. Stevenson et al., [21] randomized
43 medicated patients to an eight week cognitive
remediation therapy (CRT) group programme or treatment
as usual and found a significant effect for ADHD symp-
toms, organizational skills and reduction in feelings of
anger for those who completed the programme. The group
programme introduced the novel element of individual
coaching sessions for participants between group sessions.
The treatment gains for the CRT condition were main-
tained at one year follow up except for state anger.
The only non-randomized controlled study that has
been reported indicated that CBT can be effective even
when provided in intensive bursts. Bramham and collea-
gues [22] provided an intensive 3-day intervention (one
day per month for 3 months) to medicated patients and
compared outcome with waiting list controls. The inter-
vention included psychoeducation and CBT drawing on
modules from the Young-Bramham programme [23] on
topics of ADHD symptoms, emotional control, relation-
ship skills, time-management, problem solving, and pre-
paring for the future. A significant effect was found for
those receiving CBT on measures of psychoeducation
(an ADHD knowledge quiz), self-efficacy and self-
esteem. No significant effect was found for anxiety and
depression.
The findings from these studies suggest that the provi-
sion of psychological treatment in medicated patients -
whether delivered in individual or group sessions - is
effective in treating ADHD symptoms and has an addi-
tive effect over and above medication alone. The find-
ings for treating comorbid problems however are
limited and need to be studied further. Nevertheless
comorbidity in adult ADHD is so common that group
interventions that target symptoms, comorbid and asso-
ciated problems will have a better chance of conferring
health gain by making global improvements to self-effi-
cacy, self-esteem and quality of life. If this can be
achieved, this will be a cost-effective intervention that
may reduce multiple presentations to health care ser-
vices [6,24].
This study aimed to investigate the effectiveness of the
R&R2 ADHD cognitive behavioural group treatment
which has been developed to treat ADHD symptoms
and common comorbid problems. Medicated patients
were randomly assigned to either receive CBT (the
CBT/MED condition) or treatment as usual (TAU/MED
condition). The primary outcomes of interest were
changes in ADHD symptoms following treatment. Sec-
ondary outcome measures were anxiety, depression,
emotional control, social functioning and antisocial
behaviour. It was hypothesized that the CBT/MED con-
dition would show significantly greater improvements
than the TAU/MED condition on primary and second-
ary outcome measures and that this effect would be
maintained at follow-up.
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Methods
Participants
Participants had been referred to an outpatient rehabilita-
tion clinic within the Mental Health Services at the Land-
spitali - The National University Hospital of Iceland or
self-referred from an advertisement to members of the
Icelandic ADHD association, a national support organi-
zation. All participants were required to have a clinical
diagnosis of ADHD and to be stable on prescribed
ADHD medication for at least a month, i.e. stimulants
(immediate- or extended-release methylphenidate and
amphetamine sulphate), atomoxetine or bupropion. The
participants were told to try and keep dosages unchanged
during the whole study. Exclusion criteria included
patients with severe mental illness, active drug abuse,
verbal IQ estimated from clinical records to be below 85,
no valid ADHD diagnosis or not prescribed/taking
ADHD medication.
Out of the 92 referrals initially received, 38 were
excluded on the following grounds: 13 were off-medica-
tion, nine with a questionable diagnosis and four misusing
drugs/alcohol. A further seven declined to participate and
five either did not show up for the intake interview or they
could not be reached by phone or e-mail.
The remaining 54 participants were 34 women (mean
age 34.1, SD = 10.9) and 20 men (mean age 33.5, SD =
12.4). Of the 54 participants 33 were self-referrals and 21
were referred by psychiatrists. All participants had been
assessed and diagnosed with ADHD by mental health pro-
fessionals with expertise in diagnosing ADHD using DSM-
IV criteria. All medication was prescribed by psychiatrists.
At baseline, 42 (77.8%) participants were receiving methy-
phenidate, 11 (20.4%) were receiving atomoxetine, 5
(9.3%) were receiving bupropion, and 1 (1.9%) was receiv-
ing amphetamine sulphate. Thirteen (24.1%) participants
were receiving only one medication, 16 (29.6%) were
receiving two medications and the remaining 25 (46.3%)
were receiving three or more drugs. Participants were
asked if they had some other mental/emotional problem
and 35 (64.8%) reported depression, 20 (37%) reported
some anxiety disorder, 12 (22.2%) reported a history of
drug/alcohol abuse and nine (16.7%) reported some other




The Kiddie-Schedule for Affective Disorders and Schizo-
phrenia (K-SADS-PL) ADHD section, present and life-
time version [25] interview measures both ADHD
symptoms and impairment on functioning (home, work
and relationships) and has been modified for adults and
translated into Icelandic. Magnusson et al. [26] found
that the K-SADS was reliable and valid and had strong
correlation with self-reported and informant rated
ADHD symptoms. In the present study current symp-
toms were rated to measure symptom change. A total of
18 questions are rated on a 1-3 point scale from 1 = no
symptoms or impairment, 2 = symptoms with moderate
impairment, and 3 = symptoms indicating severe
impairment in functioning. The minimum score on the
K-SADS is 18 and 54 is the maximum score
The Clinical Global Impression (CGI; 27) is a single
question where the clinician is asked to rate severity of
illness on a 7 point scale (i.e., a score of 1 indicates not
being ill and a score of 7 indicates being extremely ill)
by comparing the patient to other patients with ADHD.
The clinician’s severity score is based on judgment
regarding impairment in functioning, symptom severity
and distress or coping and is supported by examples of
these factors [27]. The CGI has shown to correlate well
with other ADHD measures [28,29].
Self-report measures
The Barkley ADHD Current Symptoms Scale (BCS; [30])
corresponds to the DSM-IV diagnostic criteria of ADHD.
Each item was scored on a 4-point Likert scale for fre-
quency of symptoms experienced during the previous six
months. Scores range between 0 and 27 for each of the
two subscales (Inattention and Hyperactivity/Impulsivity)
and 0 to 54 for the Total scale. The scale is reported to
have good psychometric properties and correlates well
with informants’ ratings of symptoms and interview-
based diagnoses in childhood and adulthood in an Icelan-
dic sample [26].
The Beck Anxiety Inventory (BAI; [31]) is a 21-item
scale designed to assess severity of anxiety symptoms.
Items are scored on a 4 point Likert scale (0-3) where the
respondent rates how much he or she has been bothered
by various symptoms during the past week from not at all
to severely.
The Beck Depression Inventory (BDI; [32]) is a 21-item
scale where responders rate how they have been feeling
during the past week on a 4 point Likert scale (0-3).
The R&R2 ADHD Training Evaluation Self-report Scale
(RATE-S; [33]) provides four subscales: (1) ADHD symp-
toms; (2) Emotional Control; (3) Antisocial Behaviour; and
(4) Social Functioning. The RATE-S scale has been shown
to have good reliability and validity [11,34], Gudjonsson,
Sigurdsson, Adalsteinsson & Young: The relationship
between attention deficit hyperactivity disorder (ADHD)
symptoms, mood instability, and self-reported offending,
submitted).
The Intervention
R&R2ADHD [33] is a 15 session manualised CBT inter-
vention programme that was developed in 2007 for
youths and adults with ADHD and antisocial behaviour.
It is a revised edition of the 35-session Reasoning &
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Rehabilitation programme [35] that was originally devel-
oped as a prosocial competence training programme for
use in correctional facilities and its feasibility and effec-
tiveness are well supported in this population [36,37].
R&R2ADHD is a structured, manualised programme
that aims to decrease impairment of core ADHD symp-
toms and improve social, problem solving, and organiza-
tional skills. It consists of five treatment modules (1)
neurocognitive, e.g. learning strategies to improve atten-
tional control, memory, impulse control and planning,
(2) problem solving, e.g. developing skilled thinking,
problem identification, consequential thinking, managing
conflict and making choices, (3) emotional control, e.g.
managing feelings of anger and anxiety, (4) pro-social
skills, e.g. recognition of the thoughts and feeling of
others, empathy, negotiation skills and conflict resolu-
tion, and (5) critical reasoning, e.g. evaluating options
and effective behavioural skills.
The programme integrates group and individual treat-
ment, the latter being achieved by group facilitators train-
ing ‘coaches’ who meet with the participant between
sessions. The coaching role aims to support participants
to transfer skills learned in the group into their daily
lives. In the present study the coach role was fulfilled by
psychology undergraduates. This programme was deliv-
ered according to a manual and the coaches also received
directions through training and written guidelines. All
R&R2ADHD facilitators had extensive experience in CBT
and received training in delivering the programme.
Procedure
The study was conducted in line with international
guidelines, following ethical approval by the Icelandic
Bioethics Committee on 01/09/2008, reference number
08-095-S1.
All 54 participants met with the first author for an
intake interview when they gave informed consent. Of
these 51 completed the self-reported baseline measures
and 51 completed the baseline measures with the indepen-
dent evaluator. The independent evaluators were psychia-
trists who were blind to the treatment condition. They
obtained demographic information and completed the
K-SADS and CGI. Every attempt was made to maintain
the blind evaluation as both independent evaluators and
participants received repeated instructions to remind them
to avoid disclosure of whether the participant was receiv-
ing R&R2ADHD group treatment or not.
An independent psychiatrist randomly allocated the
participants to either the CBT/MED experimental condi-
tion (n = 27) or the TAU/MED control condition (n =
27). The CBT/MED condition received R&R2ADHD
group therapy in addition to continued psychopharmaco-
logical treatment. The TAU/MED condition received
psychopharmacological treatment only. At baseline no
statistical difference (two-tailed) was found between the
two conditions on dosage size of methylphenidate (t =
1.126, df = 40, p = .267), atomoxetine (t = .697, df = 9, p
= .504), age (t = -.439, df = 52, p = .662), or sex (c2 = (1,
N = 54) = 0.318, p = .573). No statistical differences were
found on any of the outcome measures at baseline
between the two conditions (p < .05).
The participants in both conditions were not asked to
refrain from engaging in other interventions during the
study period. Information about other interventions was
not collected and thus other treatments were not con-
trolled for. Treatment integrity was ensured in two ways;
first by adopting a structured manualised CBT programme
and, second, via the independent observation of a sample
of sessions by a practitioner who monitored adherence to
the manualised treatment protocol. Participants in the
CBT condition received 15 R&R2ADHD sessions twice
weekly, each lasting 90 minutes. Three groups were run in
total and coaches met with the participants once a week
for 30 minutes to review sessions and help with home-
work. Participants were re-assessed using the same mea-
sures at Time 2 (end of treatment) and Time 3 (three
month follow up). The timing of the evaluation assess-
ments was the same for the CBT/MED and TAU/MED
conditions. A log of group attendance, and reasons for
non-attendance were recorded each session. Figure 1 pre-
sents a flowchart of patient participation.
Statistical analysis
Unadjusted mean scores and standard deviations on each
of the outcome measures are provided for the CBT/MED
and TAU/MED conditions for the three assessment peri-
ods - Time 1, Time 2 and Time 3 (see Table 1). Differ-
ences between the two conditions on the outcome
measures were not statistically significant at baseline.
Nevertheless, in order to reduce error variance an analy-
sis of covariance (ANCOVA) was calculated for each of
the dependent variables measuring differences between
the conditions in time. The baseline scores therefore
served as covariates and scores at Time 2 and Time 3
served as dependent variables. Thus intention to treat
analysis (ITT) was conducted. Missing values were not
imputed because the ANCOVA calculates outcome
whilst adjusting for all baseline data. Between group
effect sizes for the outcome assessments were measured
using Cohen’s d using unadjusted means for the depen-
dent variables and SD pooled for unequal group sizes.
Fischer’s exact test was used to compare proportions of
medication changes. Since this study follows an ITT pro-
tocol, statistical analysis of the outcome variables were
completed for all participants regardless of medication
changes.
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Results
Completion Rate
Of the 27 participants who started the CBT treatment,
20 participants completed, giving a completion rate of
74%. Four dropped out during the treatment phase
without explanation, one due to moving out of the area,
one due to illness in the family and one had to stop
medication due to pregnancy. The dropout rate of 6
(22.2%) was similar for participants in the TAU/MED
condition (i.e. they did not attend the end of treatment
Figure 1 Flowchart of patient participations.
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assessment). Two participants in the CBT treatment
condition and four participants in the control condition
did not complete all of the end of treatment assess-
ments. A further three participants in the CBT treat-
ment condition but no participants in the control
condition did not complete the follow-up assessments.
A total of 35 participants completed self-reported
questionnaires at the end of treatment and 32 at three
month follow up; 34 participants attended the indepen-
dent evaluation at the end of treatment and 21 at three
month follow-up. To test for possible baseline differ-
ences between completers and non-completers a com-
parison was made on baseline IE measures between
those who completed the follow-up measures and those
who attended the baseline measures but did not com-
plete all the post assessments (two tailed). For the CBT/
MED condition there was no statistical difference at
baseline between completers (n = 8) and non-comple-
ters (n = 18) on the CGI (t = .493, df = 24, p = .626) or
on the K-SADS (t = .720, df = 24, p = .479). The same
results were found for the TAU/MED condition where
no statistical difference was found between completers
(n = 13) and non-completers (n = 12) on baseline mea-
sures of CGI (t = .419, df = 23, p = .679) or K-SADS
(t = .480, df = 23, p = .636).
Medication changes
At baseline, methylphenidate dosages ranged between
18-180 mg, with a mean dosage of 60.5 mg. By the end of
treatment, dosages had been increased for two partici-
pants in each condition and decreased for one participant
in each condition. The dosage range for methylphenidate
was 36-162 mg, with a mean dosage of 62.5 mg. At
three-month follow-up dosages had been increased for
one participant in each condition and decreased for two
in the CBT/MED condition and one in the TAU/MED
condition. The dosage range of methylphenidate at fol-
low-up was 36-108 mg, with a mean dosage of 59.4 mg.
Fischer’s exact test revealed that there were no significant
differences in proportions of medication change between
the two conditions either at the end of treatment (P =
.619) or at three month follow-up (P = .473). Table 1 pre-
sents the unadjusted means and standard deviations for
each outcome measure at baseline, at the end of treat-
ment and at three month follow up, for the experimental
(CBT/MED) and control (TAU/MED) conditions. It also
gives the effect sizes (Cohen’s d) of the mean difference
between the two conditions for the end of treatment and
three-month follow-up assessments. Adverse events were
recorded during the trial and one participant in the CBT/
MED condition reported severe distress at the end of
treatment due to changes in personal circumstances.
This participant then received individual treatment and
was not assessed at follow-up.
Effectiveness
Independent evaluators’ outcome measures (IE)
After adjusting for baseline means the CBT/MED condi-
tion had significantly lower IE ratings than the TAU/
MED condition on the K-SADS ADHD measure at the
end of treatment (F(1,31) = 11.02, p < .01) with a large
effect size. At three month follow-up a significant differ-
ence was maintained where the CBT/MED condition
had lower IE ratings than the TAU/MED condition
(F(1,18) = 7.60, p < .05) and the effect size remained
large (see Figure 2).
On the CGI no significant difference was found
between conditions at the end of treatment (p = .06)
but the CBT/MED condition had significantly lower IE
ratings at follow-up (F(1,18) = 9.16, p < .05) with a large
effect size.
Self-report outcome measures
After adjusting for baseline means the participants in the
CBT/MED condition had significantly lower scores on the
inattention scale of the BCS than those in the TAU/MED
condition at the end of treatment (F(1,32) = 8.73, p < .05)
and at three month follow-up (F(1,29) = 10.70, p < .01)
with large effects sizes. The participants in the CBT/MED
condition also scored lower on symptoms of hyperactivity/
impulsivity on the BCS both at the end of treatment
(F(1,32) = 7.27, p < .05) and at three month follow-up
(F(1,29) = 20.30, p < .001) with small and medium effect
sizes, respectively. On the total BCS score the participants
in the CBT/MED condition scored significantly lower than
those in the TAU/MED condition at the end of treatment
(F(1,32) = 10.45, p < .01) and at follow-up (F(1,29) =
17.36, p < .001) with medium and large effect sizes, respec-
tively (see Figure 3).
After adjusting for baseline means no significant dif-
ference was found on anxiety scores on the BAI between
the two conditions at end of treatment (p = .46). The
Figure 2 Independent evaluator rated changes in unadjusted
means on the K-SADS ADHD measure.
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participants in the CBT/MED condition showed how-
ever significant improvement at follow-up compared
with those in the TAU/MED condition (F(1,29) = 4,61,
p < .05) with a large effect size. On the BDI no signifi-
cant difference was found at the end of treatment (p =
.052) but the CBT/MED condition showed significant
improvement compared with the TAU/MED condition
at follow-up (F(1,29) = 5.86, p < .05) with a large effect
size.
With respect to the RATE-S Scales, no significant dif-
ference was found between the two conditions at the
end of treatment on the Total RATE-S score (p = .07)
but the CBT/MED condition scored significantly lower
than the TAU/MED condition at follow-up (F(1,28) =
14.77, p < .001) with a large effect size. The same effect
was found for the ADHD, Emotional Control and Social
Functioning Scales. No significant difference was found
between the two conditions at the end of treatment on
the ADHD Scale (p = .16) but the CBT/MED condition
scored significantly lower than the TAU/MED condition
at three month follow-up (F(1,28) = 11.83, p < .01) with
a large effect size. No significant difference was found
between the two conditions at the end of treatment on
the Emotional Control Scale (p = .48) but at follow-up
the CBT/MED condition showed significant improve-
ment compared with the TAU/MED condition (F(1,28)
= 6.35, p < .05) with a large effect size. On the Social
Functioning Scale no significant difference was found
between the two conditions at the end of treatment (p =
.09) but the CBT/MED condition showed significant
improvement compared with the TAU/MED condition
at follow-up (F(1,28) = 10.88, p < .01) with a large effect
size. On the Antisocial Scale, the CBT/MED condition
showed significant improvement compared with the
TAU/MED condition at the end of treatment (F(1,31) =
4.75, p < .05) with a large effect size. This difference
was maintained at follow-up (F(1,29) = 7.28, p < .05)
with a large effect size.
Discussion
Two important findings arise from the results. As
hypothesized there was a significant effect for improve-
ment in core ADHD symptoms at the end of treatment.
Secondly, large effects were found for treating ADHD
symptoms and comorbid problems at follow up. The
exception is the BCS hyperactivity/impulsivity scale where
the effect sizes were small to medium. It is however evi-
dent from the present findings that in spite of receiving
medication for ADHD, the participants were experiencing
significant residual symptoms which were successfully and
further improved by the CBT intervention. Safren and col-
leagues [16,17] also reported that combined treatments
have better outcomes than medication alone in treating
ADHD symptoms, depression and anxiety.
Antisocial behaviour also improved at the end of treat-
ment and at follow-up with a large effect. This is note-
worthy since participants’ baseline scores for antisocial
behaviour were relatively low for both conditions indicat-
ing the importance of the prosocial training component of
R&R2ADHD. Given the reported high rates of comorbid
antisocial problems in adult ADHD [2-4], it seems impor-
tant to include a prosocial competence component to
CBT interventions when treating people with ADHD. The
present study illustrates that even in participants who have
not been referred for antisocial behaviour, a more positive
prosocial outcome can be achieved. Alternatively, antiso-
cial participants need to be screened out of CBT interven-
tions that aim primarily to target core ADHD symptoms
of attention, impulsivity, planning and organization defi-
cits, else it is possible that improvement in functioning in
these domains may be applied to improve antisocial skills.
Significant and large treatment effects were noted on
all the self- reported measures when followed up three
months later. This was supported by the independent
evaluations of ADHD symptoms and global functioning
which had large effect sizes. For the ADHD symptoms,
effect sizes were even greater at follow up than at the
end of treatment. Thus the R&R2ADHD programme
was highly effective in treating ADHD symptoms and
common comorbid problems of anxiety, depression,
antisocial behaviour and social functioning. Improve-
ments in comorbid problems were partly significant
immediately following the end of treatment phase but
significantly and further improved during the follow-up
period. It is likely that those who completed the CBT
intervention continued to use the strategies learned in
sessions after they finished treatment and therefore the
treatment effect persisted and became greater over time.
The present study shows that the RATE-S Scales,
which are provided with the programme, are useful
Figure 3 Self-reported changes in unadjusted means on the
Barkley ADHD Current Symptom Scale.
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dynamic measures of change over time as people symp-
tomatic for ADHD learn to cope better with the emo-
tional instability associated with their symptoms. This is
in line with other studies using the RATE-S [11,34]. It
also shows that R&R2ADHD is an effective intervention
for ADHD adults attending psychiatric community ser-
vices and participants reported to facilitators that they
enjoyed attending the programme. As a structured man-
ualized programme, R&R2ADHD facilitates consistency
in delivery across different populations and settings and
maximises programme integrity. Thus the benefits of
R&R2ADHD are multifaceted and the combination of
psychopharmacological and CBT treatments may add to
and improve pharmacological interventions. This is
likely to be further enhanced by the integration of group
sessions and individual coaching sessions as a model for
programme delivery as this model provides a structured
support for the transference of skills into daily life.
The strengths of the current study are its RCT design
and the independent outcome measures used in addition
to self-report measures. There was a modest drop-out
rate for this kind of a study and the drop-out rate was
comparable between both conditions. The main limita-
tions of the study are the small numbers of participants
and the difficulties to obtain outcome measures for all
participants at the end of treatment and at follow-up.
The attrition rate for outcome measures is a common
problem with this kind of research [38].
A second limitation is that we were unable to control
for change in medication as study participants remained
under the care of their individual treating psychiatrists.
Although there were some changes in medication, these
did not significantly differ between the two conditions.
Furthermore, we did not control for the possibility that
the TAU/MED condition were receiving some other
non-pharmacological interventions.
A further limitation is that the participants in the
CBT/MED condition received more attention than the
TAU/MED participants during the treatment phase and
therefore nonspecific placebo effects could limit the
results. However, most changes occurred during the
period between the end of treatment and three month
follow-up and both conditions did not receive any con-
tact during this period.
Conclusions
The results give further support for the growing evi-
dence that CBT increases the effect of psychopharmaco-
logical treatment in reducing ADHD symptoms and
comorbid problems, and demonstrating improvements
in functions associated with impairment. These findings
support the recommendations of international guidelines
for a comprehensive treatment package that includes
psychological and psychopharmacological treatments for
adults with ADHD.
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